Synapse - Works

Results (34)

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

Journal Article

Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes

Journal Article

Praiss, A. M.; White, C.; Iasonos, A.; Selenica, P.; Zivanovic, O.; Chi, D. S.; Abu-Rustum, N. R.; Weigelt, B.; Aghajanian, C.; Girshman, J.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer

Journal Article

Zammarrelli, W. A. 3rd; Ma, W.; Espino, K.; Gordhandas, S.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N. R.; Aghajanian, C.; more...
Gynecologic Oncology (2023)

Fulltext@MSK | Save

Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

Journal Article

Manning-Geist, B. L.; Kahn, R. M.; Nemirovsky, D.; Girshman, J.; Laibangyang, A.; Gordhandas, S.; Iasonos, A.; Chui, M. H.; Long Roche, K.; Zivanovic, O.; more...
Cancer (2023)

Fulltext@MSK | Save

Phase I study of a multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission

Journal Article

Manning-Geist, B. L.; Gnjatic, S.; Aghajanian, C.; Konner, J.; Kim, S. H.; Sarasohn, D.; Soldan, K.; Tew, W. P.; Sarlis, N. J.; Zamarin, D.; more...
Cancers (2023)

Fulltext@MSK | Save

High-sensitivity mutation analysis of cell-free DNA for disease monitoring in endometrial cancer

Journal Article

Ashley, C. W.; Selenica, P.; Patel, J.; Wu, M.; Nincevic, J.; Lakhman, Y.; Zhou, Q.; Shah, R. H.; Berger, M. F.; Da Cruz Paula, A.; more...
Clinical Cancer Research (2023)

Fulltext@MSK | Save

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

Journal Article

Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
Gynecologic Oncology (2023)

Fulltext@MSK | Save

Ovarian cancer mutational processes drive site-specific immune evasion

Journal Article

Vázquez-García, I.; Uhlitz, F.; Ceglia, N.; Lim, J. L. P.; Wu, M.; Mohibullah, N.; Niyazov, J.; Ruiz, A. E. B.; Boehm, K. M.; Bojilova, V.; more...
Nature (2022)

Fulltext@MSK | Save

A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)

Meeting Abstract

Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)

Meeting Abstract

Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save